Payment overview · 2025
General Payments
$482.59
27 reported records · 5 companies
Healthcare provider profile · identity verified
Kin Wong, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1962436428
Verified facts
What the public records show
CMS Open Payments records show Kin Wong, MD received $482.59 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Trelegy Ellipta, Ztlido.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trelegy Ellipta by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $219.62 | 45.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.10 | 33.6% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.48 | 12.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.10 | 4.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.29 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.59 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $162.10 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $144.11 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.08 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.71 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 131 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
241 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
131 | 20 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
107 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 877 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 549 | 85 |
| Ezetimibe | Ezetimibe | 441 | 65 |
| Lisinopril | Lisinopril | 409 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 401 | 54 |
| Celecoxib | Celecoxib | 318 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 262 | 48 |
| Risedronate Sodium | Risedronate Sodium | 262 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 33 |
| Lokelma | Sodium Zirconium Cyclosilicate | 241 | 32 |
| Metformin Hcl | Metformin Hcl | 230 | 31 |
| Gabapentin | Gabapentin | 215 | 34 |
| Vascepa | Icosapent Ethyl | 215 | 33 |
| Azelastine Hcl | Azelastine Hcl | 213 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 22 |
| Losartan Potassium | Losartan Potassium | 172 | 24 |
| Alendronate Sodium | Alendronate Sodium | 139 | 31 |
| Pregabalin | Pregabalin | 132 | 26 |
| Naproxen | Naproxen | 131 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 128 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 18 |
| Omeprazole | Omeprazole | 121 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 114 | 34 |
| Acarbose | Acarbose | 113 | 13 |
| Meloxicam | Meloxicam | 111 | 11 |
| Ztlido | Lidocaine | 107 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 101 | 15 |
| Atenolol | Atenolol | 95 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 13 |
| Creon | Lipase/Protease/Amylase | 91 | 21 |
| Mometasone Furoate | Mometasone Furoate | 85 | 14 |
| Lansoprazole | Lansoprazole | 78 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 13 |
| Januvia | Sitagliptin Phosphate | 75 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 71 | 22 |
| Ibuprofen | Ibuprofen | 71 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 68 | 11 |
| Finasteride | Finasteride | 66 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 66 | suppressed |
| Febuxostat | Febuxostat | 63 | suppressed |
| Allopurinol | Allopurinol | 61 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | suppressed |
| Carvedilol | Carvedilol | 58 | suppressed |
| Dutasteride | Dutasteride | 56 | suppressed |
| Hydrocortisone | Hydrocortisone | 56 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 53 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | suppressed |
| Fluocinonide | Fluocinonide | 47 | 14 |
| Ketoconazole | Ketoconazole | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 42 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 17 |
| Famotidine | Famotidine | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Colchicine | Colchicine | 36 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 33 |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Linzess | Linaclotide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Nexletol | Bempedoic Acid | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $482.59 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, OTEZLA, REPATHA, TRELEGY ELLIPTA, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error